135936-36-6 Usage
Description
(R) (+) DICHLOROPHENYL AMINO ALCOHOL is a chemical compound distinguished by its molecular structure that features a dichlorophenyl group attached to an amino alcohol moiety. It is available in two enantiomeric forms, with the (R) or (+) configuration indicating the specific orientation of the molecules. (R) (+) DICHLOROPHENYL AMINO ALCOHOL is recognized for its potential chiral properties, which render it a valuable intermediate in the synthesis of pharmaceutical drugs, agrochemicals, and other fine chemicals, making it a versatile building block in the chemical and pharmaceutical industries.
Uses
Used in Pharmaceutical Industry:
(R) (+) DICHLOROPHENYL AMINO ALCOHOL is used as a chiral building block for the synthesis of complex pharmaceutical compounds. Its unique (R) or (+) configuration contributes to the development of enantiomerically pure drugs, which is crucial for ensuring the desired therapeutic effects and minimizing potential side effects associated with racemic mixtures.
Used in Agrochemical Industry:
In the agrochemical sector, (R) (+) DICHLOROPHENYL AMINO ALCOHOL is utilized as a key intermediate in the production of chiral agrochemicals. Its specific enantiomeric form allows for the creation of more effective and targeted pesticides, reducing the environmental impact and increasing the safety of these products.
Used in Fine Chemicals Production:
(R) (+) DICHLOROPHENYL AMINO ALCOHOL is employed as a versatile intermediate in the synthesis of various fine chemicals. Its chiral properties enable the production of high-quality specialty chemicals used in a range of applications, from fragrances and flavors to advanced materials and catalysts.
Used in Chiral Synthesis Research:
(R) (+) DICHLOROPHENYL AMINO ALCOHOL is used as a research compound in the field of chiral synthesis. Its unique molecular structure and enantiomeric form provide valuable insights into the development of new synthetic methods and the understanding of stereoselective reactions, contributing to the advancement of asymmetric synthesis techniques.
Check Digit Verification of cas no
The CAS Registry Mumber 135936-36-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,3,5,9,3 and 6 respectively; the second part has 2 digits, 3 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 135936-36:
(8*1)+(7*3)+(6*5)+(5*9)+(4*3)+(3*6)+(2*3)+(1*6)=146
146 % 10 = 6
So 135936-36-6 is a valid CAS Registry Number.
InChI:InChI=1/C6H5Cl2NO/c7-5-3-1-2-4-6(5)9(8)10/h1-4,10H
135936-36-6Relevant articles and documents
4-Amino-2-(aryl)-butylbenzamides and their conformationally constrained analogues. Potent antagonists of the human neurokinin-2 (NK2) receptor
MacKenzie, A. Roderick,Marchington, Allan P.,Middleton, Donald S.,Newman, Sandra D.,Selway, Christopher N.,Terrett, Nicholas K.
, p. 2211 - 2215 (2007/10/03)
A library, evaluating a range of piperazines, piperidines and acyclic amines, as replacements for the 4-hydroxy-4-phenylpiperidine moiety in lead (1b) was prepared. These efforts identified the 4-((N)-benzimidazolone)piperidine analogue (2a) which was further optimised using classical single-compound synthesis to yield the 3-((N)-morpholino)azetidine (2j). Conformationally constrained analogues of (2j), generally offered no potency advantage in this particular series.
Substituted heteroalkyleneamine neurokinin antagonists
-
, (2008/06/13)
Compounds of formula I STR1 wherein Q1, Q2, Q3, and Q4 have any of the meanings given in the specification, their N-oxides, and their pharmaceutically acceptable salts are nonpeptide antagonists of SP and NKA are useful for the treatment of asthma, etc. Also disclosed are pharmaceutical compositions, processes for preparing the compounds of formula I and intermediates.
Aryl substituted heterocycles
-
, (2008/06/13)
The present invention concerns the novel use of aryl substituted heterocycles of formula I, set out below, which antagonize the pharmacological actions of one of ent endogenous neuropeptide tachykinins an the neurokinin 2 (NK2) receptor making them useful whenever such antagonism is desired, such as in the treatment of asthma and related conditions. The invention also provides pharmaceutical compositions containing the aryl substituted heterocycles for use in such treatment. Certain novel aryl substituted heterocycles of formula I and novel intermediates for their manufacture are also provided. STR1
